CERVARIX 20 µg/0.5 mL+ 20 µg/0.5 mL suspenzija za injekciju u  napunjenoj šprici Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

cervarix 20 µg/0.5 ml+ 20 µg/0.5 ml suspenzija za injekciju u napunjenoj šprici

glaxosmithkline d.o.o.sarajevo - papilomavirus (humanitarne tipovi 16, 18) - suspenzija za injekciju u napunjenoj šprici - 20 µg/0.5 ml+ 20 µg/0.5 ml - 0,5 ml suspenzije za injekciju u napunjenoj šprici (1 doza) sadrži: 20 mcg humanog papiloma virusa tipa 16 l1 (vlp) 20 mcg humanog papiloma virusa tipa 18 l1 (vlp)

GARDASIL 20 µg/0.5 mL+ 40 µg/0.5 mL+ 40 µg/0.5 mL+ 20 µg/0.5 mL suspenzija za injekciju Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

gardasil 20 µg/0.5 ml+ 40 µg/0.5 ml+ 40 µg/0.5 ml+ 20 µg/0.5 ml suspenzija za injekciju

merck sharp & dohme bh d.o.o. - papilomavirus (humanitarne tipovi 6, 11, 16, 18) - suspenzija za injekciju - 20 µg/0.5 ml+ 40 µg/0.5 ml+ 40 µg/0.5 ml+ 20 µg/0.5 ml - 0,5 ml (1 doza) suspenzije za injekciju sadrži: 20 mcg humani papilomavirus tip 6 l1 protein 40 mcg humani papilomavirus tip 11 l1 protein 40 mcg humani papilomavirus tip 16 l1 protein 20 mcg humani papilomavirus tip 18 l1 protein

GARDASIL 20 µg/0.5 mL+ 40 µg/0.5 mL+ 40 µg/0.5 mL+ 20 µg/0.5 mL suspenzija za injekciju Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

gardasil 20 µg/0.5 ml+ 40 µg/0.5 ml+ 40 µg/0.5 ml+ 20 µg/0.5 ml suspenzija za injekciju

merck sharp & dohme bh d.o.o. - papilomavirus (humanitarne tipovi 6, 11, 16, 18) - suspenzija za injekciju - 20 µg/0.5 ml+ 40 µg/0.5 ml+ 40 µg/0.5 ml+ 20 µg/0.5 ml - 0,5 ml (1 doza) suspenzije za injekciju sadrži: 20 mcg humani papilomavirus tip 6 l1 protein 40 mcg humani papilomavirus tip 11 l1 protein 40 mcg humani papilomavirus tip 16 l1 protein 20 mcg humani papilomavirus tip 18 l1 protein

GARDASIL 20 µg/0.5 mL+ 40 µg/0.5 mL+ 40 µg/0.5 mL+ 20 µg/0.5 mL suspenzija za injekciju u  napunjenoj šprici Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

gardasil 20 µg/0.5 ml+ 40 µg/0.5 ml+ 40 µg/0.5 ml+ 20 µg/0.5 ml suspenzija za injekciju u napunjenoj šprici

merck sharp & dohme bh d.o.o. - papilomavirus (humanitarne tipovi 6, 11, 16, 18) - suspenzija za injekciju u napunjenoj šprici - 20 µg/0.5 ml+ 40 µg/0.5 ml+ 40 µg/0.5 ml+ 20 µg/0.5 ml - 0,5 ml (1 doza) suspenzije za injekciju u napunjenoj šprici sadrži: 20 mcg humani papilomavirus tip 6 l1 protein 40 mcg humani papilomavirus tip 11 l1 protein 40 mcg humani papilomavirus tip 16 l1 protein 20 mcg humani papilomavirus tip 18 l1 protein

GARDASIL 20 µg/0.5 mL+ 40 µg/0.5 mL+ 40 µg/0.5 mL+ 20 µg/0.5 mL suspenzija za injekciju u  napunjenoj šprici Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

gardasil 20 µg/0.5 ml+ 40 µg/0.5 ml+ 40 µg/0.5 ml+ 20 µg/0.5 ml suspenzija za injekciju u napunjenoj šprici

merck sharp & dohme bh d.o.o. - papilomavirus (humanitarne tipovi 6, 11, 16, 18) - suspenzija za injekciju u napunjenoj šprici - 20 µg/0.5 ml+ 40 µg/0.5 ml+ 40 µg/0.5 ml+ 20 µg/0.5 ml - 0,5 ml (1 doza) suspenzije za injekciju u napunjenoj šprici sadrži: 20 mcg humani papilomavirus tip 6 l1 protein 40 mcg humani papilomavirus tip 11 l1 protein 40 mcg humani papilomavirus tip 16 l1protein 20 mcg humani papilomavirus tip 18 l1 protein

Mvabea Europska Unija - hrvatski - EMA (European Medicines Agency)

mvabea

janssen-cilag international n.v.    - recombinant modified vaccinia ankara bavarian nordic virus encoding the: ebola virus zaire (zebov) mayinga strain glycoprotein (gp); ebola virus sudan gulu strain gp; ebola virus taï forest strain nucleoprotein and the marburg virus musoke strain gp - Геморрагическая groznice ebole - cjepiva - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.

Comirnaty Europska Unija - hrvatski - EMA (European Medicines Agency)

comirnaty

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - cjepiva - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. korištenje ovog cjepiva mora se provoditi u skladu sa službenim preporukama.

Jcovden (previously COVID-19 Vaccine Janssen) Europska Unija - hrvatski - EMA (European Medicines Agency)

jcovden (previously covid-19 vaccine janssen)

janssen-cilag international nv - adenovirus type 26 encoding the sars-cov-2 spike glycoprotein (ad26.cov2-s) - covid-19 virus infection - cjepiva - jcovden is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older. korištenje ovog cjepiva mora se provoditi u skladu sa službenim preporukama.

Vaxzevria (previously COVID-19 Vaccine AstraZeneca) Europska Unija - hrvatski - EMA (European Medicines Agency)

vaxzevria (previously covid-19 vaccine astrazeneca)

astrazeneca ab - chadox1-sars-cov-2 - covid-19 virus infection - cjepiva - vaxzevria is indicated for active immunisation to prevent covid 19 caused by sars cov 2, in individuals 18 years of age and older. korištenje ovog cjepiva mora se provoditi u skladu sa službenim preporukama.

Nuvaxovid Europska Unija - hrvatski - EMA (European Medicines Agency)

nuvaxovid

novavax cz, a.s. - sars cov-2 (original) recombinant spike protein, sars-cov-2 (omicron xbb.1.5) recombinant spike protein - covid-19 virus infection - covid-19 vaccines - nuvaxovid is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. korištenje ovog cjepiva mora se provoditi u skladu sa službenim preporukama. nuvaxovid xbb. 5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. korištenje ovog cjepiva mora se provoditi u skladu sa službenim preporukama.